French recommendations for the management of Takayasu's arteritis
- PMID: 34284801
- PMCID: PMC8293493
- DOI: 10.1186/s13023-021-01922-1
French recommendations for the management of Takayasu's arteritis
Abstract
The aim of this National Diagnostic and Care Protocol (PNDS) is to explain to the professionals involved the current optimal diagnosis and therapeutic management and care approach for a patient with Takayasu's arteritis. Its purpose is to optimize and harmonize the management and follow-up of this rare disease throughout the country. It also identifies pharmaceutical specialties used in an indication not provided for in the Marketing Authorization, as well as the specialties, products or services necessary for the care of patients but not usually paid for or reimbursed.
© 2021. The Author(s).
Conflict of interest statement
DS reports no conflicts of interest. ABR reports consulting fees/meeting fees from Bayer, Astra-Zeneca; research funding from Bayer, BMS/Pfizer. CC reports no conflicts of interest. ML reports consulting fees/meeting fees Celgène, Bayer, BMS/Pfizer, Leopharma; research funding from Bayer, Roche. AR reports consulting fees/meeting fees Horixtech Holding. TM reports consulting fees/meeting fees Pfizer.
Figures



Publication types
MeSH terms
LinkOut - more resources
Full Text Sources